Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
On February 19, 2021, Johnson & Johnson announced that Janssen-Cilag International submitted an Emergency Use Listing for its single-dose COVID-19 vaccine candidate to the WHO. This submission follows the completion of the rolling data submission process, which includes interim results from the Phase 3 ENSEMBLE trial. The vaccine aims for equitable access, especially for lower-income countries, with plans to deliver up to 500 million doses via the COVAX Facility through Gavi. The Company is dedicated to global access on a not-for-profit basis during the pandemic.
Johnson & Johnson (NYSE: JNJ) announced on February 4, 2021, that Janssen Biotech has submitted an application to the FDA for Emergency Use Authorization of its single-dose COVID-19 vaccine. This submission is based on positive results from the Phase 3 ENSEMBLE trial, which met all primary endpoints. Once authorized, the vaccine will be ready for immediate distribution. The vaccine can be stored at -4°F for two years and at refrigeration temperatures for up to three months. The company is also engaging with global health authorities for further approvals.
On January 29, 2021, Johnson & Johnson (NYSE: JNJ) announced promising topline results from its Phase 3 ENSEMBLE clinical trial of a single-dose COVID-19 vaccine. The vaccine demonstrated 66% efficacy in preventing moderate to severe COVID-19, with effectiveness varying across regions. Notably, it achieved an 85% efficacy in preventing severe disease and complete protection against hospitalization and death, 28 days post-vaccination. The company plans to apply for Emergency Use Authorization in February, aiming for rapid distribution upon approval.
Johnson & Johnson (NYSE: JNJ) reported its 2020 financial results, showing a 0.6% increase in annual sales to $82.58 billion. The fourth-quarter sales rose by 8.3% to $22.48 billion. However, net earnings fell 56.7% YoY to $1.74 billion, with EPS declining to $0.65. The pharmaceutical sector saw an 8.0% increase in operational sales, while the medical devices segment faced an 11.6% decline due to COVID-19. The company remains optimistic about its ongoing COVID-19 vaccine efforts and potential future innovations.
Johnson & Johnson (NYSE: JNJ) has announced a cash dividend of $1.01 per share for the first quarter of 2021. This dividend is set to be paid on March 9, 2021, with shareholders of record on February 23, 2021. The ex-dividend date is February 22, 2021. This announcement reflects the company's ongoing commitment to returning value to shareholders.
Johnson & Johnson (NYSE: JNJ) appointed Dr. Nadja West, a retired U.S. Army lieutenant general and former Surgeon General, to its Board of Directors on December 3, 2020. Dr. West brings extensive healthcare leadership experience, having served as the Army Surgeon General from 2015 to 2019. Her strategic vision and commitment to public health are expected to enhance the Board's capabilities. CEO Alex Gorsky expressed optimism about her contributions at a crucial time for the company's mission to improve global health.
Summary not available.
Johnson & Johnson (NYSE: JNJ) announced an expansion of its partnership with the Biomedical Advanced Research and Development Authority (BARDA) to further develop its investigational COVID-19 vaccine. Janssen will invest approximately $604 million, while BARDA will contribute $454 million, supporting the Phase 3 ENSEMBLE trial with up to 60,000 volunteers. This collaboration emphasizes the importance of public-private partnerships in addressing the COVID-19 pandemic. J&J reaffirms its commitment to ethical vaccine development and adherence to scientific standards.
Johnson & Johnson will host a virtual Medical Devices Update on November 19, 2020, at 10 a.m. ET, showcasing innovations in digital surgery. The session will feature leadership insights, including those from Ashley McEvoy, and will cover the company's strategic positioning and advancements in Orthopaedics, Surgery, Interventional Solutions, and Vision franchises. Attendees can view franchise exhibits starting November 18, 2020, at 4:30 p.m. ET. Registration is available online, and a replay will be accessible post-event on the Investor Relations section of the JNJ website.
Johnson & Johnson (NYSE: JNJ) announced a cash dividend of $1.01 per share for the fourth quarter of 2020. This dividend will be paid on December 8, 2020 to shareholders recorded by the close of business on November 24, 2020. The ex-dividend date is set for November 23, 2020. This announcement reflects the company's commitment to returning value to its shareholders amidst its ongoing operations in the health care sector.